Skip to main content
Top
Published in: Supportive Care in Cancer 11/2020

01-11-2020 | Original Article

Ketogenic and low-sugar diets for patients with cancer: perceptions and practices of medical oncologists in Canada

Authors: Pamela N. Klassen, Benjamin A. Goldenberg, Pascal Lambert, Kathy Vagianos, Christina A. Kim

Published in: Supportive Care in Cancer | Issue 11/2020

Login to get access

Abstract

Purpose

Many patients with cancer are interested in complementary therapies, including strategies such as reduced carbohydrate diets. Guidelines regarding the use of these diets during cancer treatment are lacking; therefore, we aimed to explore the perceptions and practices of medical oncologists in Canada regarding low-sugar and ketogenic diets.

Method

A cross-sectional, online multiple-choice survey was distributed to 206 Canadian medical oncologists. Questions explored frequency of patient interactions, oncologist perceptions of efficacy, advice given to patients, and concerns about side effects related to reduced carbohydrate diets.

Results

Responses were received from 57 medical oncologists in seven of thirteen provinces and territories, with an overall response rate of 28%. Forty-nine percent of respondents were asked at least weekly about a low-sugar diet, and 9% about the ketogenic diet. Eighty-five percent supported the use of a low–added sugar diet in patients with diabetes or hyperglycemia, while conversely 87% did not support the use of a ketogenic diet for any of their patients undergoing active cancer treatment. Respondents felt either that a ketogenic diet was not effective (31%) or that the effect on cancer outcomes was unknown (69%). Ninety-six percent of respondents had concerns about a ketogenic diet for patients receiving active cancer treatment.

Conclusion

The role of reduced carbohydrate diets during cancer treatment is topical. Canadian oncologists are particularly reluctant to support a ketogenic diet for patients on active cancer treatment, with concerns about side effects and unknown efficacy. There may be a role for continuing medical education and institutional guidelines to inform these discussions with patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Canadian Cancer Statistics Advisory Committee (2019) Canadian Cancer Statistics 2019. Toronto, ON Canadian Cancer Statistics Advisory Committee (2019) Canadian Cancer Statistics 2019. Toronto, ON
4.
go back to reference Zick SM, Snyder D, Abrams DI (2018) Pros and cons of dietary strategies popular among cancer patients. Oncology 32:542–547PubMed Zick SM, Snyder D, Abrams DI (2018) Pros and cons of dietary strategies popular among cancer patients. Oncology 32:542–547PubMed
8.
go back to reference The World Health Organization (W.H.O.) (2018) Guideline: sugars intake for adults and children The World Health Organization (W.H.O.) (2018) Guideline: sugars intake for adults and children
9.
go back to reference WCRF/AICR (2018) Diet, nutrition, physical activity and cancer: a global perspective WCRF/AICR (2018) Diet, nutrition, physical activity and cancer: a global perspective
26.
go back to reference Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hütterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Mühlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC (2016) ESPEN guidelines on nutrition in cancer patients. Clin Nutr 36:11–48. https://doi.org/10.1016/j.clnu.2016.07.015CrossRefPubMed Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hütterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Mühlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC (2016) ESPEN guidelines on nutrition in cancer patients. Clin Nutr 36:11–48. https://​doi.​org/​10.​1016/​j.​clnu.​2016.​07.​015CrossRefPubMed
Metadata
Title
Ketogenic and low-sugar diets for patients with cancer: perceptions and practices of medical oncologists in Canada
Authors
Pamela N. Klassen
Benjamin A. Goldenberg
Pascal Lambert
Kathy Vagianos
Christina A. Kim
Publication date
01-11-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05361-9

Other articles of this Issue 11/2020

Supportive Care in Cancer 11/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine